EML4 and non-small cell lung carcinoma: Notably, the evidence that F-circEA mainly exists in the plasma of EML4-ALK-positive NSCLC patients suggests that F-circEA could be a potentially novel biomarker for the diagnosis of EML4-ALK-positive NSCLC patients.